Business context and reporting period
BioRestorative Therapies, Inc. develops cell-based therapies, including BRTX-100 for disc and spine conditions and a preclinical brown-fat program. Despite the request metadata identifying 2020 Q1, this filing covers the three and nine months ended September 30, 2020 (Q3 and nine-month results), compared with the same periods in 2019. The filing was signed April 12, 2021. The company filed for Chapter 11 on March 20, 2020; its reorganization plan was confirmed October 30 and became effective November 16, 2020, after the reporting date.
Financial results and liquidity
| Metric | Q3 2020 | Q3 2019 | Nine months 2020 | Nine months 2019 |
|---|---|---|---|---|
| Revenue | $15,000 | $38,000 | $60,000 | $98,000 |
| Operating expenses | $625,265 | $1,856,996 | $1,957,611 | $6,374,136 |
| Operating loss | $(610,265) | $(1,818,996) | $(1,897,611) | $(6,276,136) |
| Net loss | $(836,263) | $(5,056,973) | $(5,511,375) | $(13,097,335) |
| Operating cash flow | Not separately presented | $(1,392,145) | $(5,107,743) |
Revenue was entirely royalty revenue under a sublicense agreement. Revenue and operating expenses were both small relative to losses; operating margins were negative. The MD&A gives an inconsistent nine-month operating loss of $(897,611); the financial statements show $(1,897,611), which reconciles revenue to operating expenses.
At September 30, cash was $175,994, current assets $214,434, total assets $1,428,943, and working-capital deficiency approximately $15.86 million. Total liabilities were $16.52 million, including $14.70 million classified as liabilities subject to compromise in bankruptcy and $1.115 million of DIP financing. The balance sheet showed a $15.09 million stockholders’ deficit. Cash increased by $174,330 during the first nine months, primarily due to $1.115 million of DIP proceeds and other financing; investing cash flow was zero. No meaningful profit margin was reported.
Common shares outstanding rose from 77.9 million at December 31, 2019 to 1.595 billion at September 30, 2020, largely from debt exchanges. The filing reports 3.176 billion shares outstanding as of April 7, 2021. This substantial dilution, along with subsequent plan warrants and convertible securities, is important to assess.
Material changes versus prior period
- Nine-month revenue fell 39% to $60,000. Operating expenses declined about 69%, reflecting steep cuts to marketing, consulting, R&D and general and administrative costs before and during Chapter 11.
- Nine-month net loss narrowed to $5.51 million from $13.10 million. Lower operating costs and lower debt-related charges contributed, while the 2020 period also included a $2.14 million loss from changes in derivative fair value and a $597,919 net reorganization gain.
- Operating cash use fell to $1.39 million from $5.11 million. The company reported $441,762 of note proceeds and $1.115 million of DIP financing during the period.
- Prepetition debt and other claims were reclassified as liabilities subject to compromise. The plan subsequently exchanged about $14.7 million of claims for common shares and new convertible notes and warrants, among other treatments; those post-quarter transactions do not represent September 30 balances.
Outlook, risks and unusual items
- Management expected operating losses and negative operating cash flow to continue. It anticipated resuming development activity and increasing R&D and G&A costs after emergence from Chapter 11.
- The company intended to start a Phase 2 BRTX-100 clinical study in Q3 2021, subject to obtaining funding. It estimated at least $12 million would be needed to commence and complete the Phase 2 study, and approximately $45 million of additional funding for the full clinical trials, assuming no revenue.
- Management stated that post-reorganization funding and a conditional Auctus commitment supported cash sufficiency for 12 months after filing. The additional Auctus funding was subject to conditions, including becoming current in SEC reporting. The filing cautions that funding may be inadequate or unavailable and that operations could be curtailed or discontinued.
- Plan financing included secured convertible notes bearing 7% interest and unsecured convertible notes bearing 5%, generally convertible at a market-based price, plus large warrant packages. Secured notes are backed by substantially all company assets. These instruments create financing, repayment and potential dilution risks.
- Significant unusual accounting items included bankruptcy reorganization charges and gains, debt-discount amortization, note-extinguishment losses and derivative remeasurement/write-offs. The statements were prepared on a going-concern basis despite substantial doubt-related liquidity conditions.
- Management reported ineffective disclosure controls and internal control over financial reporting, citing inadequate segregation of duties, formal-policy weaknesses and insufficient risk assessment. The filing also says the required controls evaluation had not been completed.
- The company disclosed no off-balance-sheet arrangements considered material and no litigation it believed would materially adversely affect results. It described a Coventry Enterprises court matter and a potential share-issuance contingency; investors should review the outcome and related disclosures.
Most important facts for investors to verify
- Confirm the reporting period: this is a September 30, 2020 Form 10-Q, not a 2020 Q1 report, and verify the inconsistent operating-loss figure in MD&A against the financial statements.
- Review the confirmed Chapter 11 plan, actual funding received and remaining conditional Auctus commitment, including restrictions and repayment/conversion terms.
- Assess cash runway and funding needs against the stated $12 million Phase 2 and approximately $45 million clinical-development estimates.
- Calculate potential dilution from the post-quarter shares, convertible notes, plan warrants and equity awards; reconcile these with the April 2021 share count.
- Track BRTX-100 trial timing and funding, and evaluate the consequences if the company cannot raise sufficient capital.
- Review remediation of the disclosed material weaknesses and the status of SEC reporting compliance, which is also a condition tied to additional funding.